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NADPH oxidaseCardiac oxidative stress has been implicated in the pathogenesis of hypertrophy, cardiomyopathy and heart
failure. Systemic deletion of the gene encoding adipose triglyceride lipase (ATGL), the enzyme that catalyzes
the rate-limiting step of triglyceride lipolysis, results in a phenotype characterized by severe steatotic cardiac
dysfunction. The objective of the present study was to investigate a potential role of oxidative stress in
cardiac ATGL deﬁciency. Hearts of mice with global ATGL knockout were compared to those of mice with
cardiomyocyte-restricted overexpression of ATGL and to those of wildtype littermates. Our results demonstrate
that oxidative stress, measured as lucigenin chemiluminescence, was increased ~6-fold in ATGL-deﬁcient hearts.
In parallel, cytosolic NADPH oxidase subunits p67phox and p47phox were upregulated 4–5-fold at the protein
level. Moreover, a prominent upregulation of different inﬂammatory markers (tumor necrosis factor α, mono-
cyte chemotactant protein-1, interleukin 6, and galectin-3) was observed in those hearts. Both the oxidative
and inﬂammatory responses were abolished upon cardiomyocyte-restricted overexpression of ATGL. Investigat-
ing the effect of oxidative and inﬂammatory stress on nitric oxide/cGMP signal transduction we observed a
~2.5-fold upregulation of soluble guanylate cyclase activity and a ~2-fold increase in cardiac tetrahydrobiopterin
levels. Systemic treatment of ATGL-deﬁcient mice with the superoxide dismutase mimetic Mn(III)tetrakis
(4-benzoic acid) porphyrin did not ameliorate but rather aggravated cardiac oxidative stress. Our data suggest
that oxidative and inﬂammatory stress seems involved in lipotoxic heart disease. Upregulation of soluble
guanylate cyclase and cardiac tetrahydrobiopterinmight be regarded as counterregulatorymechanisms in cardi-
ac ATGL deﬁciency.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license. /−), adipose triglyceride lipase
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Cardiac lipotoxicity is regarded as sum of various cell-damaging
processes: Besides disruption of organelle membranes and activation
of the apoptotic machinery, ER stress and oxidative stress have been
identiﬁed as crucial components of the lipotoxic response [1]. Different
enzymatic sources of oxidative stress including NADPH oxidase (for
review, see [2]), uncoupled nitric oxide synthase (NOS; [3]), and
xanthine oxidase [4], have been implicated in the development of cardi-
ac dysfunction. Recent evidence points to an essential role of NADPH
oxidases (NAD(P)H:oxygen oxidoreductases; EC 1.6.3.1) as mediators
of lipid-driven oxidative stress. Thus, diet-induced obesity in rats
resulted in ectopic fat deposition and concomitant upregulation of the
NADPH oxidase 2 (NOX2) system in liver and heart [5]. Similarly, a
previous study on Lep/Lep mice, a genetic model of obesity, suggested
that cardiac contractile dysfunction is related to enhanced NOX2-
dependent oxidative stress [6]. Besides NOX2, NOX4 has been described
as the second important NADPH oxidase isoform in the heart. However,
its distinct role in cardiac pathophysiology is unclear yet, since both license. 
1601A. Schrammel et al. / Biochimica et Biophysica Acta 1831 (2013) 1600–1608beneﬁcial and harmful effects have been demonstrated in different
animal models of NOX4 overexpression or knockout [7,8].
With the recent discovery of adipose triglyceride lipase (ATGL) a key
enzyme of triglyceride catabolism was identiﬁed [9]. ATGL catalyzes
the initial step of the triglyceride lipolysis cascade i.e. the hydrolytic
cleavage of triacylglycerols (TGs) into free fatty acids (FFAs) and diacyl-
glycerols (DAGs). The enzyme is predominantly expressed in adipose
tissue, but it is also present to a lesser extent in cardiac muscle,
skeletal muscle, and other tissues. Systemic ablation of ATGL in mice
(ATGL(−/−)) yielded a phenotype with increased whole body fat mass
and neutral lipids accumulating in adipose and non-adipose tissues
[10]. In cardiac muscle, ATGL deﬁciency caused an age-dependent
increase of myocyte lipid droplets in number and size. In parallel,
echocardiographic analysis demonstrated the progressive development
of ventricular hypertrophy with abnormal myocardial texture and
systolic dysfunction [10]. Using Langendorff perfusion of isolated hearts
we have recently demonstrated that the contractile and microvascular
response to ß-adrenergic stimulation was drastically reduced in ATGL
deﬁciency [11]. Contrariwise, transgenic mice with supraphysiological
protein expression of ATGL in cardiomyocytes (WT/MHC-A35) showed
reduced triglyceride levels in the heart as well as improved basal pump
function and protection against experimentally induced pathophysiolog-
ical stress [12].
Concerning the prevalence of obesity- and diabetes-related human
cardiomyopathy that is characterized by myocardial fat deposition and
compromised contractile function, ATGL-deﬁcient and overexpressing
mice are invaluable tools to study lipotoxic heart disease. Using these
animal models we aimed to investigate the potential role of oxidative
stress in the development and progression of lipid-driven cardiomyopa-
thywith special emphasis on the speciﬁc role of cardiac NADPHoxidases.
2. Theory
ATGL(−/−)mice suffer from severe cardiac function due to abnormal
accumulation of triglycerides within cardiomyocytes. Since oxidative
stress has been identiﬁed as crucial component of cardiac lipotoxicity in
experimental animals [5,6] we hypothesized that a similar mechanism
might be operative in ATGL-deﬁcient hearts. The theory will be tested
on the one hand by identifying potential sources of oxidative stress and
on the other hand by chronic treatment of animals with a superoxide
dismutase mimetic.
3. Materials and methods
3.1. Materials
2,2-Diethyl-1-nitroso-oxyhydrazine (DEA/NO), 1-benzyl-3-(5-
hydroxymethylfur-2-yl) indazole (YC-1) and Mn(III)tetrakis (4-
benzoic acid) porphyrin chloride (MnTBAP) (Enzo Life Sciences
AG, Lausen, Switzerland) were purchased through Eubio (Vienna,
Austria). Antibodies were purchased as indicated: NOX2 and
p67phox (BD Transduction Laboratories, Heidelberg, Germany);
p47phox (Novus Biologicals, Cambridge, UK); VASP (Cell Signaling
through New England Biolabs, Frankfurt, Germany); NOX4 (Abcam,
Cambridge, UK); pVASP (Calbiochem through VWR, Vienna, Austria);
Mac-2 (galectin-3; Cedarlane through Szabo-Scandic, Vienna, Austria);
phosphorylated protein kinase C (PKC; pan; Thr 410 of human PKCζ;
Cell Signaling); GAPDH (Sigma, Vienna, Austria). [3H]L-Arginine
(40 Ci/mmol) and [α-32P]GTP (400 Ci/mmol) were obtained from
PerkinElmer (Vienna, Austria); gp91ds-tat was synthesized by piChem
(Graz, Austria). ChemiGlow™ was obtained from Biozym (Vienna,
Austria). Protease Inhibitor Cocktail tablets (Complete™) were from
Roche (Vienna, Austria). Materials for real-time PCR experiments
were fromApplied Biosystems (Vienna, Austria). GenElute™Mammalian
Total RNA Miniprep Kit, RIPA buffer, and all other chemicals were from
Sigma (Vienna, Austria).3.2. Animals
Homozygous ATGL(−/−) mice [10] and corresponding wild-type
(WT) littermates were used for this study. In addition, WT and
ATGL(−/−) mice with cardiomyocyte-speciﬁc overexpression of
ATGL termed WT/MHC-A35 mice and ATGL(−/−)/MHC-A35 mice,
respectively [12,13], were used for most experiments. After weaning,
animals received standard laboratory mouse chow and water ad
libitum. Mice were housed in approved cages and kept on a regular
12 h dark/light cycle. Animals were sacriﬁced at 9 weeks of age.
Hearts were dissected, cleaned, and frozen for further biochemical
analysis. All animals received care in accordance with the Austrian
law on experimentation with laboratory animals (last amendment,
2012),which is based on the USNational Institutes of Health guidelines.
3.3. MnTBAP treatment
WT and ATGL(−/−) mice (aged 6 weeks) were treated with
MnTBAP (5 mg × kg−1 × d−1; i.p.) dissolved in phosphate-buffered
saline (PBS) as vehicle once per day for 3 weeks. Application of vehicle
toWT and ATGL(−/−)mice had no effect. After sacriﬁce of the animals,
hearts were excised and plasma was collected and frozen for biochem-
ical analysis. Cardiac and plasma MnTBAP levels were measured by
HPLC as described [14]. The protocol was approved by the Austrian Fed-
eral Ministry for Science and Research (BMWF-66.007/0002-II/3b/
2012).
3.4. NADPH oxidase activity
Hearts were homogenized in 10 volumes of PBS containing
Complete™ using a glass potter Elvehjem homogenizer. Total homoge-
nates (50–100 μg of protein) were incubated in PBS containing
diethylenetriamine pentaacetic acid (100 μM) at 37 °C for 30 min in
the absence or presence of the NADPH oxidase inhibitor gp91ds-tat
(50 μM) [15], the SOD mimetic MnTBAP (10 μM) or Cu, Zn SOD
(500 U/ml). Thereafter, NADPH (300 μM) was added to activate
NADPH oxidases, followed by addition of lucigenin at a non-redox
cycling concentration of 5 μM [16]. Lucigenin-derived chemilumines-
cence was measured every 10 s for 3 min using a TriCarb® 2100TR
Liquid Scintillation Counter (PerkinElmer, Vienna, Austria). Results
were corrected for protein-deﬁcient blanks and expressed as cpm per
μg protein.
3.5. Determination of NOS activity
Hearts were homogenized in 10 volumes of a 50 mM
triethanolamine/HCl buffer (pH 7.4) containing 1% (v/v) ß-
mercaptoethanol, 10 mM 3-[(3-cholamidopropyl)dimethyl-ammonio]-
1-propanesulfonate, 0.5 mM EDTA and Complete™ with a glass potter
Elvehjem homogenizer. Homogenates were centrifuged at 10,000 g for
10 min at 4 °C. Supernatants were assayed for NOS activity as conversion
of [3H]L-arginine to [3H]L-citrulline as previously described [17]. Results
were corrected for enzyme-deﬁcient blanks and recovery of L-citrulline.
3.6. Real-time PCR
Total RNA was isolated from homogenized hearts using the
GenElute™ Mammalian Total RNA Miniprep Kit including DNAse
treatment of samples. RNA was transcribed to cDNA using the High
Capacity cDNA Reverse Transcription Kit. Real-time PCR analysis
was performed with ~25 ng cDNA using TaqMan® Universal PCR
Master Mix and pre-designed TaqMan® Gene Expression Assays for
NOX2 (Mm 00432775_m1), NOX4 (Mm 00479246_m1), tumor ne-
crosis factor α (TNFα; Mm 00443258_m1), monocyte chemotactic
protein-1 (MCP-1; Mm 00441243_g1), and interleukin 6 (IL-6; Mm
00446190_m1). Reactions were carried out on a 7300 Real-Time
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were as follows: 2 min at 50 °C, 10 min at 95 °C, and 40 cycles of 15 s at
95 °C and 1 min at 60 °C. Data were analyzed according to the 2−ΔΔCt
method using cyclophilin (Mm 00835365_g1) as the reference gene.
Lack of ampliﬁcation was veriﬁed in no-template controls.
3.7. Western blot analysis
Denatured samples containing 20 μg of protein were separated by
SDS-PAGE (8% gel) and transferred onto nitrocellulose membranes.
After blocking, membranes were probed with antibodies raised against
NOX2 (1:5000), NOX4 (1:1000), p67phox (1:5000), p47phox (1:750),
pPKC (pan; 1:1000), VASP (1:1000), pVASP (1:1000), Mac-2 (1:5000),
or GAPDH (1:50,000), followed by treatment with horseradish
peroxidase-conjugated anti-rabbit IgG for NOX2, NOX4, p47phox, pPKC,
and VASP (1:5000), anti-mouse IgG for p67phox, pVASP, and GAPDH
(1:5000) or anti-rat (1:5000) for Mac-2. Immunoreactive bands were
visualized by chemiluminescence using ChemiGlow™ and quantiﬁed
densitometrically using the E.A.S.Y. Win 32 software (Herolab, Vienna,
Austria).
3.8. Determination of sGC activity
Hearts were homogenized in 10 volumes of a 50 mM
triethanolamine/HCl buffer (pH 7.4), supplemented with 2 mM
dithiothreitol, 2 mM EDTA and Complete™, using a glass potter
Elvehjem homogenizer. After centrifugation at 10,000 g for 15 min
(4 °C), supernatants were removed and centrifuged at 100,000 g for
1 h (4 °C). For determination of sGC activity, cytosols (20–60 μg)
were incubated for 20 min at 37 °C in a total volume of 0.1 ml of
a 50 mM triethanolamine/HCl buffer (pH 7.4), containing 0.1 mM
[α-32P]GTP (~300,000 cpm), 5 mM MgCl2, 1 mM cGMP, 1 mM
isobutylmethylxanthine, 1 mM EGTA, 2 mM dithiothreitol, 5 mM crea-
tine phosphate, and 15 mU of creatine phosphokinase. Reactions were
started with 0.1 mM DEA/NO or a combination of 0.1 mM DEA/NO
and 0.1 mM YC-1. Basal activity was assayed in the presence of 5 mM
MnCl2. Reactions were terminated by ZnCO3 precipitation, and [32P]
cGMPwas isolated by column chromatography as described previously
[18]. Results were corrected for enzyme-deﬁcient blanks and recovery
of cGMP.
3.9. Determination of cardiac cGMP levels
Frozen hearts (30–50 mg) were pulverized using a dismembrator
and extracted in 5% trichloroacetic acid. Samples were centrifuged at
4000 g for 15 min at 4 °C. Supernatants were collected and washed
three times for 5 min with water-saturated ether. Cardiac cGMP
was quantiﬁed by radioimmunoassay as described [19].
3.10. Determination of cardiac BH4 and BH2
Frozen hearts (40–50 mg) were homogenized with 8 volumes of a
chilled mixture containing 100 mM HClO4 and 85 mM H3PO4 using a
glass potter Elvehjem homogenizer. Homogenates were centrifuged
for 10 min at 20,000 g (4 °C). Supernatants (50 μl) were oxidized
under acidic and alkaline conditions with 10 μl of a mixture of
0.1 M I2 and 0.5 M KI at ambient temperature for 60 min in the
dark. Subsequently, excess I2 was eliminated with 10 μl of 0.2 M
ascorbic acid and samples were neutralized with either 1 M NaOH
or 1.7 M H3PO4. After centrifugation at 20,000 g for 5 min (4 °C),
samples were loaded onto a LiChrospher 100 RP 18 HPLC column,
5 μm particle size (Merck, Darmstadt, Germany), using a mixture of
95% NaH2PO4 (20 mM, pH 3.0) and 5% methanol as mobile phase
(ﬂow rate of 1 ml/min). Pteridines were quantiﬁed with a ﬂuores-
cence detector at excitation and emission wavelengths of 350 and
440 nm, respectively, by interpolation using a calibration curve thatwas measured daily with authentic BH4 (5–300 nM). Data were
expressed as pmol per g wet weight.
3.11. Staining of cardiac lipids
Heart specimens were ﬁxed with 2.5% glutaraldehyde in 0.01 M
cacodylate buffer pH 7.3. After dehydration, specimens were embed-
ded in Agar 100 resin (Plano, Wetzlar, Germany). Semi-thin sections
(1 μm) were stained with azur-methylene blue according to standard
methods.
3.12. Protein quantiﬁcation
Protein concentrations were either measured by the method of
Bradford [20] or using the Thermo Scientiﬁc Pierce BCA™ Protein
Assay Kit (Fisher Scientiﬁc Austria GmbH, Vienna, Austria).
3.13. Statistics
Data are presented as mean values ± S.E.M. Student's t-test (un-
paired) was applied for single comparisons. One-way ANOVA follow-
ed by Student–Newman–Keuls post-hoc test was applied for multiple
comparisons. Differences were assumed to be signiﬁcant for p b 0.05.
4. Results
4.1. NADPH oxidase-derived oxidative stress in ATGL deﬁciency
The involvement of NADPH oxidase-derived oxidative stress in
ATGL deﬁciency was probed by comparing gp91ds-tat-sensitive
chemiluminescence in cardiac homogenates from WT, ATGL(−/−),
WT/MHC-A35 and ATGL(−/−)/MHC-A35 mice. As shown in Fig. 1A,
knockout of ATGL resulted in more than 6-fold higher chemilumines-
cence indicating signiﬁcantly increased NADPH oxidase activity.
Cardiomyocyte-speciﬁc overexpression of ATGL completely reversed
the effect of ATGL deﬁciency. Presence of the selective NADPH oxi-
dase inhibitor gp91ds-tat (50 μM) diminished chemiluminescence
by 73.1 ± 10.0 and 84.3 ± 4.5% in homogenates of WT and
ATGL(−/−) hearts, respectively (Fig. 1A; inset). A comparable extent
of inhibition was observed with the SOD mimetic MnTBAP (10 μM)
whereas Cu, Zn SOD (500 U/ml) was less efﬁcient (Fig. 1A, inset). In-
creased NADPH oxidase activity was accompanied by upregulated
mRNA expression of the catalytic NOX2 subunit in ATGL-deﬁcient
hearts (Fig. 1B; inset). At the protein level, NOX2 expression tended
to increase in ATGL deﬁciency but the observed difference did not
reach statistical signiﬁcance (p = 0.071) (Fig. 1B). Protein expression
of the cytosolic activator subunits p47phox (Fig. 1C) and p67phox
(Fig. 1D), which initiate enzyme activation by the stoichiometric assem-
bly with the plasma membrane-attached p22phox/NOX2 heterodimer,
was signiﬁcantly increased in ATGL deﬁciency, with 5.4 ± 0.4 and
4.4 ± 0.3-fold higher protein levels of p47phox (Fig. 1C) and p67phox
(Fig. 1D), respectively. The effect of ATGL deﬁciency on NADPH oxidase
subunit expression was reversed upon overexpression of ATGL in
cardiomyocytes (Fig. 1B, C, D). Fig. 2 shows the effect of ATGL deﬁciency
on NOX4 mRNA and protein expression. NOX4 mRNA was raised
~3-fold in ATGL(−/−) hearts (Fig. 2A), and a signiﬁcant increase of
50% was observed at the protein level (Fig. 2B).
4.2. Inﬂammatory markers are upregulated in ATGL deﬁciency
To test whether proinﬂammatory processes are involved in cardiac
ATGL deﬁciency we measured mRNA levels of the well-established
markers TNFα, MCP-1, and IL-6. As illustrated in Fig. 3A, ATGL deﬁcien-
cy led to a ~3-fold increase in TNFα mRNA expression. For the
chemotactant protein MCP-1, an even more pronounced effect was
observed as mRNA levels were elevated ~17-fold as compared to WT
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Fig. 1. NOX2-dependent oxidative stress in cardiac ATGL deﬁciency. (A) gp91ds-tat-sensitive lucigenin chemiluminescence was measured in cardiac homogenates prepared from
WT (open bars), ATGL(−/−) (solid bars), WT/MHC-A35 (striped bars), and ATGL(−/−)/MHC-A35 mice (gray bars) as described in Materials and methods. Data represent mean
values ± S.E.M. of 4 individual experiments. Inset: Inhibition of NADPH-induced chemiluminescence by gp91ds-tat (50 μM), Cu, Zn SOD (500 U/ml) or MnTBAP (10 μM) in hearts
of WT (open bars) and ATGL(−/−) mice (solid bars). (B) Cardiac NOX2mRNA and protein expression were measured by qPCR andWestern blot, respectively. Data are expressed as
folds of WT controls (WT = 1) and represent mean values ± S.E.M. of 6 experiments. qPCR measurements were performed in triplicates. (C, D) Protein expression of p47phox and
p67phox subunits, respectively. Data are expressed as folds of WT controls (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments. (E) Representative Western
blots of NOX2, p47phox, p67phox, and GAPDH; *p b 0.05 ATGL(−/−) vs WT.
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cytokine IL-6 was raised nearly 4-fold in ATGL(−/−) hearts (Fig. 3C).
The proinﬂammatory response to ATGL deﬁciency was abolished by
cardiomyocyte-speciﬁc overexpression of ATGL. As shown in Fig. 3D
and F, protein expression of Mac-2, a lectin that has been implicated0
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cial threonine located in the activation loop. Threonine phosphorylation
was increasedmore than 2-fold in cardiac homogenates of ATGL(−/−)
mice (Fig. 3E and F). The effect of ATGL deﬁciency on PKC phosphoryla-
tion was reversed by cardiomyocyte-restricted overexpression of ATGL.
4.3. Cardiac NO/cGMP signaling
The potential consequences of oxidative stress for cardiac NO/cGMP
signaling in ATGL deﬁciencywere studied bymeasuring various parame-
ters characteristic for different steps of the signaling cascade. As
shown in Fig. 4A, cardiac NOS activity determined as conversion of
L-arginine to L-citrulline was not affected by any genetic manipula-
tion. Ca2+-independent activity was not detectable (data not
shown), arguing against signiﬁcant iNOS expression in any experimental
group. Protein expression of eNOS and nNOS was not affected (data not
shown). However, activity of sGC, the major downstream target of
NOS-derived NO, was signiﬁcantly increased in ATGL(−/−) hearts
(Fig. 4B). Basal cGMP formation measured in the presence of Mn2+ was
increased from 0.023 ± 0.002 to 0.077 ± 0.011 nmol × mg−1 × min−1
(Fig. 4B; inset). Upon stimulation with the NO donor DEA/NO or
co-stimulation with the NO-sensitizing drug YC-1 [23], the rates of
cGMP formation were enhanced ~2.6- and ~2.4-fold, respectively. Thus,sGC activity was signiﬁcantly increased at different activation states of
the enzyme. Cardiac-speciﬁc overexpressionofATGL resulted in sGCactiv-
ities identical to that of WT animals (Fig. 4B). Quantiﬁcation of cardiac
cGMP by radioimmunoassay showed that, despite the signiﬁcantly higher
sGC activity in ATGL(−/−) hearts, cGMP levels were virtually identical in
all experimental groups (Fig. 4C). Similarly, cGMP-dependent phosphory-
lation of vasodilator-stimulated phosphoprotein (VASP) at serine 239,
which represents a reliable biochemical marker of the NO/cGMP pathway
[24], was not affected (Fig. 4D).
4.4. Cardiac BH4 levels are increased in ATGL deﬁciency
Oxidative stress generated in the course of different vascular and
metabolic disorders may cause depletion of the essential NOS cofactor
BH4 [25–27]. Reduced intracellular availability of BH4 leads to
uncoupling of NOS i.e. the production of superoxide instead of NO,
thereby aggravating the oxidative burden. To investigate whether
this occurs in ATGL deﬁciency, we measured cardiac biopterin levels.
Paradoxically, BH4 levels were actually increased ~2-fold in ATGL
deﬁciency (Fig. 5A). In hearts, exclusively overexpressing ATGL in
cardiomyocytes, BH4 values were comparable to those of WT animals.
By contrast, cardiac BH2 was not signiﬁcantly affected by any genetic
manipulation (Fig. 5B). Calculations of the BH4/BH2 ratio showed a
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difference did not reach statistical signiﬁcance (Fig. 5C).4.5. MnTBAP did not reverse the effects of ATGL deﬁciency
As shown previously [14], systemic application of the SOD mimetic
MnTBAP [28,29] toWT and ATGL(−/−) mice resulted in pharmacolog-
ically effective tissue concentrations of the drug (data not shown).
However, MnTBAP treatment did not reverse but rather exacerbated
ATGL deﬁciency-mediated oxidative stress (Fig. 6A). With respect to
cardiac biopterins, a similarly adverse effect of the compound was ob-
served:MnTBAP-treatment of ATGL(−/−) mice resulted in a reduction
of BH4 levels similar to thosemeasured inWT hearts (Fig. 6B). Likewise,
MnTBAP treatment of ATGL(−/−) mice resulted in a decline of the
cardiac BH4/BH2 ratio to values observed in WT animals (Fig. 6C).0
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The present study was designed to investigate the role of oxida-
tive stress in cardiac dysfunction of ATGL(−/−) mice. Our data
suggest considerable upregulation of NOX2/p47phox/p67phox subunit
expression in those hearts, which was associated with increased su-
peroxide production evident as chemiluminescence sensitive to the
selective peptide inhibitor gp91ds-tat. Upregulation of NOX2 mRNA
expression suggests the involvement of a transcriptional mechanism.
Cardiomyocyte-speciﬁc overexpression of ATGL resulted in complete
reversal of NADPH oxidase upregulation, conﬁrming that the observed
effect was causally related to ATGL deﬁciency. Concerning the cardiac
phenotype of the animal model [10], these results agree well with
previous reports showing that activation of NOX2-dependent NADPH
oxidase contributes to the progression of cardiac hypertrophy in heart
failure [30,31].0
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ﬁcult to interpret since the role of this isoform in cardiac function is
discussed ambiguously [7,8]. Following the concept of Zhang and
colleagues [8], increased expression of NOX4 is protective against
chronic overload stress with the speciﬁc function to preserve myo-
cardial capillary blood ﬂow by inducing angiogenesis. On the other
hand, exacerbation of cardiac dysfunction, ﬁbrosis, and apoptosis
in response to pressure overload has been observed in experimental
animals with cardiomyocyte-speciﬁc overexpression of NOX4 [7].
Therefore, additional work is necessary to elucidate the speciﬁc
role of NOX4 in cardiac ATGL deﬁciency.
Cardiac oxidative stress was accompanied by increased expres-
sion of TNFα, MCP-1, and IL-6 pointing to inﬂammatory processes
involved in ATGL(−/−) hearts. In addition, prominent upregulation
of cardiac Mac-2, a lectin that is highly expressed and secreted by
macrophages and monocytes [32] and induces chemotactic, phago-
cytic, and lipid scavenging processes [33–35] points to severe chron-
ic cardiac inﬂammation.
Concerning the important role of NO/cGMP signaling in cardiac
function and assuming that enhanced superoxide production might
compromise this pathway we studied whether this signaling route
is affected by ATGL deﬁciency. Two major effects were observed:
ATGL deﬁciency resulted in signiﬁcant upregulation of sGC activity
and increased levels of BH4. Latter ﬁnding was quite unexpected as
it disagrees with the concept that oxidative stress is invariably ac-
companied by depletion of BH4. However, chronic administration of
BH4 to mice suffering from experimentally induced heart disease
was reported to result in marked suppression of cardiac remodeling
and hypertrophy as well as in reduced oxidative stress [36]. More-
over, enhanced BH4 biosynthesis in cardiomyocytes was described
as adaptive response to proinﬂammatory stimuli [37]. Therefore, in
ATGL deﬁciency, increased cardiac BH4 biosynthesis and/or recycling
may serve as an endogenous protective mechanism against tissue inju-
ry caused by oxidative and inﬂammatory stress with the overall aim to
maintain the cellular redox equilibrium. The molecular mechanisms
that ﬁnally result in increased BH4 levels in ATGL deﬁciencymight com-
prise enhanced de novo synthesis via the GTP cyclohydrolase pathway
and/ormore efﬁcient BH4 recycling by dihydrofolate reductase. Howev-
er, elucidation of thesemechanismswas beyond the scope of this study.
Different explanations are conceivable to link ATGL deﬁciency to
oxidative inﬂammatory stress and increased sGC activity (Scheme 1).
Conceivably, severely impaired peroxisome proliferator receptor α
(PPARα) signaling in ATGL deﬁciency [38] may initiate a sequelae of
events that eventually lead to the observed effects. Thus, downregulation
of PPARα signaling has been demonstrated to favor the development ofcardiomyocyte hypertrophy ([39], path 1). Interestingly, mice lacking
PPARα have been described to develop cardiac dysfunction due to oxida-
tive stress ([40], path 2). Moreover, the PPARα-deﬁcient cardiac pheno-
type is characterized by enhanced expression of proinﬂammatory and
ﬁbrotic markers [39] not unlike our observations with ATGL(−/−)
mice (path 3). Elevation of cardiac TNFα levels has been associated
with enhanced expression/activation of NADPH oxidases in the course
of chronic ventricular remodeling ([41], path 4).
Protein kinase C (PKC) has been described as important mediator
of TNFα-induced NADPH oxidase activation [42]. In ATGL-deﬁcient
hearts, activation of PKCs measured as phosphorylation of a crucial
threonine was increased more than 2-fold, indeed suggesting that
PKCs link upregulation of TNFα to NADPH oxidase activation. Further
studies are necessary to characterize the type of PKC involved, its
activation pattern as well as to clarify if systemic inhibition of PKCs
(e.g. by ruboxistaurin) ameliorates cardiac oxidative inﬂammatory
stress in ATGL(−/−) mice.
Concerning the strong evidence that cGMP is antihypertrophic
(for review, see [43]), increased sGC activity might serve to counter-
act the hypertrophic effects of ATGL deﬁciency (path 6). Alternatively,
sGC might be activated as a stress response to enhanced superoxide
formation by cardiac NADPH oxidases. Superoxide will scavenge NO
to form peroxynitrite ([44], path 7), a reaction that efﬁciently out-
competes formation of ferrous-nitrosyl-sGC and consequent enzyme
activation [45]. In return, cardiac sGC could be activated to maintain
cGMP signaling despite reduced NO bioavailability.
Albeit our data suggest that absence of distinct FFA-derived PPARα
ligands accounts for oxidative and inﬂammatory processes in ATGL de-
ﬁciency, pronounced accumulation of lipids in cardiac sections of
ATGL(−/−)mice (Fig. S1; supplement) implies an alternative signaling
route: It is feasible that lipid droplets per se contribute to the induction
of the oxidative inﬂammatory response. Lipid droplets contain cell-type
speciﬁc surface-binding proteins with distinct functions that have not
fully been characterized thus far. Recently, perilipin 5, a lipid droplet
coating protein, that is highly expressed in the heart has been reported
to suppress the oxidative burden in this tissue [46]. Thus, distinct alter-
ations in lipid droplet proteome might serve as signal to induce oxida-
tive and inﬂammatory mechanisms.
For unknown reasons and contrary to expectations, systemic treat-
ment of ATGL(−/−) mice with the SOD mimetic MnTBAP did not
ameliorate but rather aggravated cardiac oxidative stress as determined
in vitro. The drug was chosen on the basis of results from in vitro
experiments demonstrating effective inhibition of superoxide produc-
tion in WT and ATGL(−/−) hearts (Fig. 1A, inset). Moreover, a recent
study on PPARγ(−/−) mice convincingly demonstrated prevention of
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Scheme 1. Signaling pathways that link cardiac ATGL deﬁciency to oxidative inﬂammatory stress and increased sGC activity. Impaired PPARα signaling in ATGL deﬁciency induces
cardiac hypertrophy (path 1) that is compensated by increased sGC activity (path 6). Impaired PPARα signaling leads to increased superoxide production by NADPH oxidases (path
2) and augmented expression of inﬂammatory markers (path 3). Elevated TNFα levels induce expression of cardiac NADPH oxidases via activation of PKC (path 4). Lipid droplet
surface-binding proteins directly initiate oxidative and inﬂammatory processes (path 5). NADPH oxidase-generated superoxide scavenges NO to form ONOO− (path 7). Reduced
NO availability induces activation of cardiac sGC. NADPH oxidase-derived superoxide production enhances cardiac hypertrophy and contractile dysfunction (path 8).
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[47]. The inability of the compound to exert its protective effects in the
ATGL-deﬁcient animal model may originate from insufﬁcient reactivity
or steric hindrance in a lipid-overloaded cellular environment. Alterna-
tively, there have been reports questioning the quality, composition and
reactivity of commercially available MnTBAP [48,49]. Follow-up studies
with NADPH oxidase inhibitors such as gp91ds-tat [15] or with antioxi-
dants such as or apocynin [50] or TEMPOL [51] are necessary to clarify
the role of oxidative stress in lipotoxic heart disease.
In summary, our data demonstrate that ATGL deﬁciency
(i) upregulates NADPH oxidase expression and superoxide formation,
(ii) increases expression of inﬂammatory markers, (iii) increases BH4
levels and the BH4/BH2 ratio, and (iv) upregulates sGCwithout affecting
cardiac cGMP levels and VASP phosphorylation. These results suggest
that the adverse effects of ATGL deﬁciency on cardiac performance
involve oxidative and inﬂammatory stress.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbalip.2013.07.004.
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